Content
05/13/2025
Cambridge, MA USA
Stylus Medicine
completed $85 million Series A Round funding. Investors include
RA Capital Management, Khosla Ventures, Eli Lilly and Company, Johnson & Johnson Innovation, Chugai Venture Fund.
About
Stylus Medicine is developing transformative in vivo genetic medicines to unlock cures. Stylus combines engineered recombinases with non-viral delivery to specifically encode therapeutics. The company’s approach is versatile and modular, with potential therapeutic application across oncology, autoimmune, genetic diseases, and beyond.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
